Cardiovascular Individuals and Cardiovascular Dysfunction

Ioannis Skalidis^*
*Correspondence: Ioannis Skalidis, Department of Cardiology, Lausanne University Hospital, Lausanne, Switzerland, Email:

Keywords

Cardiovascular dysfunction • Arrhythmias • Nutritional interventions • Endothelium

Introduction

Aging is associated with a myriad of structural and functional changes in the cardiovascular system, collectively referred to as age-related cardiovascular dysfunction. The arteries lose their elasticity, becoming stiffer and less capable of accommodating changes in blood pressure. The heart's left ventricle may undergo hypertrophy, which can impair its ability to pump blood effectively. The inner lining of blood vessels, called the endothelium, becomes less efficient at producing nitric oxide, a molecule that helps dilate blood vessels. Excessive collagen deposition in the heart and blood vessels can impair their function. The heart's ability to respond to increased demands, such as during exercise or stress, diminishes. These age-related changes increase the risk of developing conditions such as hypertension, atherosclerosis, heart failure and arrhythmias. Sirtuins are a family of proteins that have garnered significant attention in the field of aging research due to their role in regulating cellular processes associated with longevity and agerelated diseases. There are seven known sirtuins in mammals each with unique functions and cellular localization. SIRT1, the most extensively studied member of the sirtuin family, is primarily located in the nucleus and cytoplasm and has been implicated in various cellular processes. Given the central role of autophagy in cardiovascular health and its decline with age, several interventions have been explored to enhance autophagic activity and mitigate age-related cardiovascular dysfunction. Identifying novel targets to mitigate these age-related changes is of paramount importance. Autophagy, the cellular process responsible for maintaining proteostasis, mitochondrial quality, lipid metabolism, and inflammation, emerges as a promising novel target for agerelated cardiovascular dysfunction [1].

Literature Review

SIRT1 can deacetylate histones and transcription factors, modulating gene expression and influencing processes such as inflammation, oxidative stress and metabolism. SIRT1 is involved in DNA repair mechanisms, helping to maintain genomic stability. SIRT1 can regulate cellular senescence, a state of irreversible growth arrest associated with aging and age-related diseases. SIRT1 is known to regulate metabolic pathways, including glucose and lipid metabolism. SIRT1 plays a pivotal role in the cardiovascular system, where it influences a wide range of processes relevant to age-related cardiovascular dysfunction. SIRT1 promotes endothelial function by increasing nitric oxide production and reducing oxidative stress and inflammation in blood vessels. This supports vasodilation and helps maintain healthy blood pressure. SIRT1 has been shown to reduce arterial stiffness by protecting against elastin degradation and promoting vascular smooth muscle cell relaxation. SIRT1 can inhibit the development of cardiac hypertrophy, a common feature of agerelated cardiovascular dysfunction, by regulating genes involved in cardiac growth and remodeling. SIRT1 helps mitigate oxidative stress by activating antioxidant defense mechanisms, reducing damage to the heart and blood vessels. Strategies to enhance autophagic activity, including caloric restriction, pharmacological agents, exercise, nutritional interventions and genetic manipulation, have shown potential in preclinical studies [2].

Discussion

SIRT1's anti-inflammatory properties are particularly relevant to cardiovascular health, as chronic inflammation is a common feature of agerelated CVD. Experimental studies have provided compelling evidence for the potential therapeutic role of SIRT1 activation in age-related cardiovascular dysfunction. Research in animal models has demonstrated that overexpression or activation of SIRT1 can ameliorate age-related cardiovascular changes, including arterial stiffness, cardiac hypertrophy, and endothelial dysfunction. Resveratrol, a natural polyphenol found in red wine and certain foods, is a known SIRT1 activator. Studies have suggested that resveratrol supplementation can improve cardiovascular health by enhancing SIRT1 activity. Several synthetic compounds that activate SIRT1 have been developed and studied in preclinical models, showing promise in mitigating age-related cardiovascular dysfunction. Caloric restriction, a dietary intervention known to extend lifespan and improve metabolic health, has been linked to SIRT1 activation and has shown cardiovascular benefits in animal studies. SIRT1 activity has been proposed as a potential biomarker of aging, and interventions aimed at enhancing SIRT1 function could have broader antiaging effects beyond the cardiovascular system. Autophagy can suppress inflammation by clearing inflammasomes and damaged cellular components that trigger the release of proinflammatory cytokines. Autophagy is involved in maintaining endothelial function, which is critical for vascular health. Aging is associated with a decrease in autophagic activity, resulting in the accumulation of damaged cellular components. If successful, these approaches could pave the way for innovative therapies to promote cardiovascular health and extend healthy aging in an increasingly elderly population [3].

While the preclinical evidence supporting SIRT1 as a novel target for agerelated cardiovascular dysfunction is promising, several challenges must be addressed before translating these findings into clinical practice. Developing pharmacological agents that selectively target SIRT1 without affecting other sirtuins or cellular processes is a significant challenge. The long-term safety of SIRT1 activation therapies needs thorough evaluation to ensure they do not promote adverse effects. Clinical trials are needed to determine the efficacy of SIRT1-based interventions in improving cardiovascular outcomes in aging individuals and those with age-related cardiovascular dysfunction. Identifying the optimal timing for initiating SIRT1-based interventions is critical, as cardiovascular changes begin decades before clinical symptoms appear. It may be necessary to explore combination therapies that target multiple mechanisms of age-related cardiovascular dysfunction. As research into SIRT1 and its role in age-related cardiovascular dysfunction continues, several important avenues for further investigation become apparent. Developing robust biomarkers of SIRT1 activity and assessing their clinical utility in predicting cardiovascular risk and treatment response. Investigating the potential for individualized treatment plans based on a person's SIRT1 activity and genetic profile. The term is derived from the Greek words signifying the self-eating nature of this process. Autophagy helps maintain protein homeostasis by eliminating misfolded or aggregated proteins that can impair cellular function [4].

Conducting long-term, prospective studies to assess the effects of SIRT1 activation on cardiovascular outcomes and overall longevity in aging populations. Gaining a deeper understanding of the specific mechanisms through which SIRT1 influences age-related cardiovascular dysfunction and identifying downstream targets for therapeutic interventions. Sirtuin 1 is emerging as a promising novel target for age-related cardiovascular dysfunction. This protein, known for its role in regulating cellular homeostasis and longevity, has shown significant potential in mitigating age-related changes in the cardiovascular system. Preclinical studies and emerging clinical evidence suggest that SIRT1 activation may improve endothelial function, reduce arterial stiffness, and inhibit cardiac hypertrophy, offering hope for new therapeutic approaches to address age-related cardiovascular diseases. However, translating these findings into clinical practice requires rigorous research, including clinical trials, to assess safety and efficacy fully. The pursuit of SIRT1-based interventions represents a compelling avenue in the quest to promote healthy aging and reduce the burden of age-related cardiovascular dysfunction. Cardiovascular diseases remain a significant global health concern, particularly in aging populations. Age-related cardiovascular dysfunction is a complex and multifaceted issue that encompasses various structural and functional changes in the heart and blood vessels. Autophagy plays a crucial role in the selective removal of damaged mitochondria preventing the accumulation of dysfunctional mitochondria associated with oxidative stress and cardiovascular diseases. Autophagy regulates lipid metabolism by controlling the degradation and recycling of lipid droplets and lipoproteins, thereby impacting atherosclerosis development [5].

As the world's population continues to age, there is a growing need to identify novel therapeutic targets to mitigate age-related cardiovascular decline. This article explores a promising novel target for age-related cardiovascular dysfunction, delving into the underlying mechanisms, potential interventions, and implications for improving the cardiovascular health of aging individuals. Age is a primary risk factor for cardiovascular diseases. As individuals grow older, their risk of developing conditions such as hypertension, atherosclerosis, heart failure, and arrhythmias increases. Agerelated cardiovascular dysfunction encompasses various processes. Aging is associated with structural alterations in the heart and blood vessels, such as ventricular hypertrophy, fibrosis, and arterial stiffening. The heart's ability to contract and pump blood efficiently may diminish with age, leading to reduced cardiac output. Aging can alter the electrical properties of the heart, potentially leading to arrhythmias. Aging is often accompanied by endothelial dysfunction, impairing blood vessel dilation and contributing to hypertension and atherosclerosis. Chronic low-grade inflammation is a hallmark of aging and can promote atherosclerosis and heart disease. Autophagy is an essential cellular process involved in the degradation and recycling of damaged or dysfunctional cellular components, including organelles and proteins. It plays a pivotal role in maintaining cellular homeostasis, promoting longevity, and protecting against various age-related diseases, including cardiovascular disorders [6].

Conclusion

Some drugs, such as rapamycin and metformin, have been investigated for their potential to enhance autophagy and delay aging-related cardiovascular changes. Regular physical activity has been associated with increased autophagic activity and improved cardiovascular health in aging individuals. Certain dietary compounds, such as resveratrol and spermidine, have been studied for their potential to modulate autophagy and promote cardiovascular health. Genetic approaches, such as overexpressing autophagy-related genes, have been explored in animal models to assess their impact on cardiovascular aging. Developing interventions that specifically enhance cardiovascular autophagy without affecting other critical cellular processes is challenging but essential. Many of the interventions that have shown promise in animal models must be rigorously tested in humans to evaluate their safety and efficacy. Considering the multifaceted nature of age-related cardiovascular dysfunction, combination therapies that target autophagy along with other relevant pathways may hold greater potential. Ethical considerations must be taken into account when translating autophagy-enhancing interventions to human populations, particularly in the context of aging and longevity. Age-related cardiovascular dysfunction presents a significant public health challenge as the global population continues to age. Further research and clinical trials are needed to assess the safety and efficacy of autophagy-targeting interventions in humans.

Acknowledgement

None.

Conflict of Interest

None.

References

1. Amaki, T., T. Suzuki, F. Nakamura and D. Hayashi, et al. "Circulating malondialdehyde modified LDL is a biochemical risk marker for coronary artery disease."Heart90 (2004): 1211-1213.

   Google Scholar, Crossref, Indexed at

2. Amioka, Naofumi, Toru Miyoshi, Hiroaki Otsuka and Daisuke Yamada, et al. "Serum malondialdehyde-modified low-density lipoprotein levels on admission predict prognosis in patients with acute coronary syndrome undergoing percutaneous coronary intervention."J Cardiol 74 (2019): 258-266.

   Google Scholar, Crossref, Indexed at

3. Brinkley, Tina E., Barbara J. Nicklas, Alka M. Kanaya and Suzanne Satterfield, et al. "Plasma oxidized low-density lipoprotein levels and arterial stiffness in older adults: The health, aging, and body composition study."Hypertension53 (2009): 846-852.

   Google Scholar, Crossref, Indexed at

4. Nagayama, Daiji, Yasuhiro Watanabe, Atsuhito Saiki and Kohji Shirai, et al. "Lipid parameters are independently associated with Cardio–Ankle Vascular Index (CAVI) in healthy Japanese subjects."J Atheroscler Thromb 25 (2018): 621-633.

   Google Scholar, Crossref, Indexed at

5. Jimi, Shiro, Keijiro Saku, Noriko Uesugi and Noriyuki Sakata, et al. "Oxidized low density lipoprotein stimulates collagen production in cultured arterial smooth muscle cells."Atherosclerosis116 (1995): 15-26.

   Google Scholar, Crossref, Indexed at

6. Amaki, T., T. Suzuki, F. Nakamura and D. Hayashi, et al. "Circulating malondialdehyde modified LDL is a biochemical risk marker for coronary artery disease."Heart90 (2004): 1211-1213.

   Google Scholar, Crossref, Indexed at